Here’s what you should know:
1. The company is in the process of validating two clinical trials, in an attempt to earn a CE Mark.
2. If successful, the company plans to launch a frontline CRC screening product sometime in 2018.
3. Volition’s CEO Cameron Reynolds said in a release the product launch will be the company’s “largest near-term opportunity.” He added the European market has 150 million-plus residents of screening age.
4. Volition is in the midst of a U.S.-based study as well. The company is conducting a 13,500 patient study with the Early Detection Research Network and Rockville, Md.-based U.S. National Cancer Institute.
More articles on gastroenterology:
GI leader to know: Dr. Francis Farraye of Boston Medical Center
Stock market week-in-review for 5 large GI companies — Sept. 11-15
Patient engagement, case conference less effective in IBD care than perceived
